Toxicity, Response and Survival in Older Patients with Metastatic Melanoma Treated with Checkpoint Inhibitors †

SIMPLE SUMMARY: Trials suggest no differences in immunotherapy treatment between older and younger patients, but mainly young patients with a good performance status were included in these trials. The aim of this study was to describe the treatment patterns and outcomes of “real-world” older patient...

Descripción completa

Detalles Bibliográficos
Autores principales: de Glas, Nienke A., Bastiaannet, Esther, van den Bos, Frederiek, Mooijaart, Simon P., van der Veldt, Astrid A. M., Suijkerbuijk, Karlijn P. M., Aarts, Maureen J. B., van den Berkmortel, Franchette W. P. J., Blank, Christian U., Boers-Sonderen, Marye J., van den Eertwegh, Alfonsus J. M., de Groot, Jan-Willem B., Haanen, John B. A. G., Hospers, Geke A. P., Jalving, Hilde, Piersma, Djura, van Rijn, Rozemarijn S., ten Tije, Albert J., Vreugdenhil, Gerard, Wouters, Michel W. J. M., Portielje, Johanneke E. A., Kapiteijn, Ellen W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8201158/
https://www.ncbi.nlm.nih.gov/pubmed/34198950
http://dx.doi.org/10.3390/cancers13112826

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8201158/
https://www.ncbi.nlm.nih.gov/pubmed/34198950
http://dx.doi.org/10.3390/cancers13112826

Ejemplares similares